DNER and cancer: It is worth mentioning that both ASBDs inhibited cancer cell viability/survival at multi-fold lower concentrations (IC50 values within the range 0.62–18.77 μM) than TMZ, a chemotherapeutic agent undergoing several clinical trials for potential application in the treatment of patients with relapsed/refractory NB [8,46,47], and RMS [48,49,50], showing the promising clinical relevance of the studied Bet derivatives (Figure 2C and Table 1).